Changes in Hong Kong stocks | Danno Pharmaceutical-B (06872) rose more than 15% in early trading, rifuquinone phase IIa proof of concept data positive, phase IIb clinical approval for launch

The Zhitong Finance App learned that Danuo Pharmaceutical-B (06872) rose more than 15% in early trading. As of press release, it rose 4.46% to HK$175.5, with a turnover of HK$14.22,900.

According to the news, on September 7, Danno Pharmaceuticals announced that the company is developing the world's first three-target drug, rifoquinone (TNP-2092). The phase IIa proof-of-concept clinical trial for intra-articular injection to treat artificial joint infections (PJI) received positive top-line results. Based on this proof of concept data, the multi-center phase IIb clinical trial has been approved by the State Drug Administration and officially launched recently.

It is worth noting that on September 7, the Shenzhen Stock Exchange announced that according to the relevant provisions of the “Shenzhen Stock Exchange Shenzhen-Hong Kong Stock Exchange Business Implementation Measures”, Hong Kong Stock Exchange's securities list was adjusted and will take effect from September 7. Among them, Danno Pharmaceuticals was included in the Hong Kong Stock Connect list. This inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of share transactions.